FG-2216 is a almighty HIF-prolyl hydroxylase inhibitor with IC50 of 3.9 uM for PDH2 enzyme; orally bioavailable and induced cogent and capricious Epo consecration in vivo.
FG-2216 was orally bioavailable and induced cogent and capricious Epo consecration in vivo (82- to 309-fold at 60 mg/kg). Abiding articulate dosing in macho rhesus macaques was able-bodied tolerated, decidedly added erythropoiesis, and prevented anemia induced by account phlebotomy.
Furthermore, bashful increases in HbF-containing red beef and reticulocytes were approved by breeze cytometry, admitting cogent increases in HbF were not approved by high-pressure aqueous chromatography (HPLC) .
more about: FG-2216
from: Pharmaceutical Ingredients
No comments:
Post a Comment